Literature DB >> 26269155

[Epidemiology of prostate cancer in China: an overview and clinical implication].

Dingwei Ye1, Yao Zhu.   

Abstract

Prostate cancer is a currently common disease in Chinese male. The incidence is increasing rapidly in urban area and the mortality is high in rural area. According to characteristics of disease stage, advancement in early diagnosis of prostate cancer is the key to improve prostate cancer survival in China. Because of the remarkable disparity in economic and health care across mainland China, a selective prostate cancer screen approach may be a better alternative to spread. Therefore, indepth researches in optimization of prostate specific antigen screen and validation biomarkers of aggressive prostate cancer should be advocated. Furthermore, physicians should take a more active role in population education.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26269155

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  19 in total

1.  The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway.

Authors:  Yan-Ping Zhang; Kai-Long Liu; Zhan Yang; Bao-Sai Lu; Jin-Chun Qi; Zhen-Wei Han; Yue-Wei Yin; Ming Zhang; De-Min Chen; Xiao-Wei Wang; Wei Li; Hong Xin
Journal:  Cell Cycle       Date:  2019-08-25       Impact factor: 4.534

2.  Assessing cancer-specific anxiety in Chinese men with prostate cancer: psychometric evaluation of the Chinese version of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC).

Authors:  Qingmei Huang; Ping Jiang; Zijun Zhang; Jie Luo; Yun Dai; Li Zheng; Wei Wang
Journal:  Support Care Cancer       Date:  2017-06-22       Impact factor: 3.603

3.  68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.

Authors:  Shiming Zang; Guoqiang Shao; Can Cui; Tian-Nv Li; Yue Huang; Xiaochen Yao; Qiu Fan; Zejun Chen; Jin Du; Ruipeng Jia; Hongbin Sun; Zichun Hua; Jun Tang; Feng Wang
Journal:  Oncotarget       Date:  2017-02-14

4.  Ultrasound‑targeted microbubble destruction‑mediated miR‑205 enhances cisplatin cytotoxicity in prostate cancer cells.

Authors:  Dingwen Qin; Haige Li; Honglin Xie
Journal:  Mol Med Rep       Date:  2018-07-24       Impact factor: 2.952

5.  Assessment on clinical value of prostate health index in the diagnosis of prostate cancer.

Authors:  Guangying Zhang; Yanyan Li; Chao Li; Na Li; Zhanzhan Li; Qin Zhou
Journal:  Cancer Med       Date:  2019-07-17       Impact factor: 4.452

6.  Identification of Pannexin 2 as a Novel Marker Correlating with Ferroptosis and Malignant Phenotypes of Prostate Cancer Cells.

Authors:  Duwu Liao; Guang Yang; Yuan Yang; Xueyong Tang; Haixia Huang; Jichun Shao; Qi Pan
Journal:  Onco Targets Ther       Date:  2020-05-19       Impact factor: 4.147

7.  Pre- and intra-operative predictors of postoperative hospital length of stay in patients undergoing radical prostatectomy for prostate cancer in China: a retrospective observational study.

Authors:  Qingmei Huang; Ping Jiang; Lina Feng; Liping Xie; Shuo Wang; Dan Xia; Baihua Shen; Baiye Jin; Li Zheng; Wei Wang
Journal:  BMC Urol       Date:  2018-05-18       Impact factor: 2.264

8.  Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.

Authors:  Junxiao Liu; Biao Dong; Wugong Qu; Jiange Wang; Yue Xu; Shuanbao Yu; Xuepei Zhang
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

9.  Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer.

Authors:  Zheng Zhang; Ciman Chai; Tianyu Shen; Xiaoqing Li; Junpeng Ji; Changying Li; Zhiqun Shang; Yuanjie Niu
Journal:  Dis Markers       Date:  2019-09-03       Impact factor: 3.434

10.  Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer.

Authors:  Qier Xia; Jun Li; Zhenyu Yang; Dingguo Zhang; Jinjun Tian; Bin Gu
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.